Tower Research Capital (TRC)’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-11,494
| Closed | -$51.8K | – | 5688 |
|
|
2025
Q2 | $51.8K | Buy |
11,494
+6,474
| +129% | +$29.1K | ﹤0.01% | 2942 |
|
|
2025
Q1 | $22.2K | Buy |
5,020
+3,378
| +206% | +$19.6K | ﹤0.01% | 2861 |
|
|
2024
Q4 | $12.9K | Sell |
1,642
-3,748
| -70% | -$45.6K | ﹤0.01% | 3577 |
|
|
2024
Q3 | $70.9K | Sell |
5,390
-1,512
| -22% | -$19.2K | ﹤0.01% | 2509 |
|
|
2024
Q2 | $83.4K | Buy |
6,902
+3,516
| +104% | +$47.5K | ﹤0.01% | 2710 |
|
|
2024
Q1 | $55.1K | Sell |
3,386
-3,300
| -49% | -$44.5K | ﹤0.01% | 2208 |
|
|
2023
Q4 | $45.6K | Buy |
6,686
+5,185
| +345% | +$30K | ﹤0.01% | 3195 |
|
|
2023
Q3 | $8.18K | Buy |
1,501
+88
| +6% | +$512 | ﹤0.01% | 4382 |
|
|
2023
Q2 | $9.59K | Sell |
1,413
-4,486
| -76% | -$33.6K | ﹤0.01% | 4249 |
|
|
2023
Q1 | $30K | Buy |
5,899
+5,323
| +924% | +$21.7K | ﹤0.01% | 3006 |
|
|
2022
Q4 | $3K | Sell |
576
-1,008
| -64% | -$7.32K | ﹤0.01% | 5252 |
|
|
2022
Q3 | $23K | Sell |
1,584
-2,600
| -62% | -$43.1K | ﹤0.01% | 3830 |
|
|
2022
Q2 | $63K | Buy |
4,184
+1,304
| +45% | +$15.2K | ﹤0.01% | 2676 |
|
|
2022
Q1 | $34K | Sell |
2,880
-295
| -9% | -$3.03K | ﹤0.01% | 3043 |
|
|
2021
Q4 | $52K | Buy |
3,175
+932
| +42% | +$19.9K | ﹤0.01% | 2735 |
|
|
2021
Q3 | $64K | Buy |
2,243
+448
| +25% | +$14.1K | ﹤0.01% | 2765 |
|
|
2021
Q2 | $61K | Sell |
1,795
-2,254
| -56% | -$72.4K | ﹤0.01% | 2864 |
|
|
2021
Q1 | $122K | Buy |
4,049
+1,250
| +45% | +$51.2K | ﹤0.01% | 2437 |
|
|
2020
Q4 | $138K | Buy |
2,799
+1,832
| +189% | +$84.7K | ﹤0.01% | 2055 |
|
|
2020
Q3 | $37K | Sell |
967
-1,716
| -64% | -$68.3K | ﹤0.01% | 3656 |
|
|
2020
Q2 | $116K | Buy |
+2,683
| New | +$101K | ﹤0.01% | 2325 |
|
|
2020
Q1 | – | Sell |
-552
| Closed | -$17K | – | 4025 |
|
|
2019
Q4 | $17K | Buy |
+552
| New | +$16.3K | ﹤0.01% | 2042 |
|
|
2019
Q3 | – | Sell |
-740
| Closed | -$17K | – | 4570 |
|
|
2019
Q2 | $17K | Buy |
740
+525
| +244% | +$12.1K | ﹤0.01% | 2281 |
|
|
2019
Q1 | $6K | Sell |
215
-142
| -40% | -$3.12K | ﹤0.01% | 2983 |
|
|
2018
Q4 | $7K | Buy |
+357
| New | +$8.2K | ﹤0.01% | 2726 |
|
Other funds holding YMAB
Tower Research Capital (TRC)'s YMAB Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 11,494 shares — an estimated $51.8K sold.
Tower Research Capital (TRC) first reported a position in YMAB in Q4 2018 and held it in 25 quarters. The position peaked at $138K in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 11,494 Y-mAbs Therapeutics shares in Q3 2025, an estimated $51.8K.
- Tower Research Capital (TRC) first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 25 quarters.
- Tower Research Capital (TRC)'s Y-mAbs Therapeutics position peaked at $138K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.